Search
Hengrui Medicine: Subsidiary's HRS-1893 Tablet Clears Clinical Trial Approval
2025-07-24 /
Read about 0 minute
Author：小编
Shandong Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, has secured approval from the National Medical Products Administration (NMPA) for the clinical trial of HRS-1893 Tablets. The company anticipates initiating these trials in the near future. HRS-1893 Tablets are designed to treat heart failure with preserved ejection fraction, a condition for which no comparable medications currently exist in the domestic or international markets. To date, approximately RMB 60.67 million has been allocated to research and development efforts related to the HRS-1893 Tablet project. Notably, the drug will only be made available on the market after successfully completing clinical trials and obtaining final approval from the NMPA.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
